SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics emerged from a singular technological insight: that genetically engineered animals could produce fully human antibodies more efficiently and reliably than the cell-culture methods that dominate the therapeutics industry. The company was born from research at San Diego State University and has spent its life trying to translate that insight into approved medicines and a sustainable business. The antibody-therapeutics space is large and lucrative, but it is also crowded with well-funded competitors. SAB’s bet is that its transgenic-animal platform offers a genuine advantage in speed and quality of antibody production — and that advantage can translate into drugs that reach patients faster and work better.

The founding platform and early years

SAB Biotherapeutics was founded in 1998 as Medarex, Inc., a company built around transgenic technology developed by researchers at San Diego State University. The core innovation was the creation of genetically modified animals — primarily transchromosomic cattle — that carried the human genes responsible for antibody production. When these animals were exposed to a pathogen or antigen, their immune system would generate fully human antibodies rather than bovine ones. This was not trivial: standard monoclonal-antibody therapeutics are often chimeric or humanized — meaning they contain parts of mouse or other animal antibodies spliced into a human framework — and those non-human components can trigger immune responses in patients. Fully human antibodies, by contrast, are recognized by the body as native, reducing the chance of rejection or allergic reactions.

The company initially pursued this technology as a means to accelerate antibody discovery for clinical use. Rather than immunizing mice and running traditional hybridoma screening, researchers could immunize the transgenic cattle and harvest human antibodies from their blood. The throughput was higher, the antibodies were native human, and the development timeline was theoretically shorter. In the early 2000s, Medarex made a name for itself by producing antibodies licensed by larger pharmaceutical companies; its most famous product was involved in the research that led to the drug ipilimumab, later commercialized by Bristol-Myers Squibb as Yervoy, a breakthrough immunotherapy for melanoma.

However, Medarex never fully capitalized on its proprietary technology. In 2006, it was acquired by Bristol-Myers Squibb, and the transgenic-antibody platform was subsumed into the larger organization. For years, SAB existed in a quieter form within BMS. But the core science and the commercial potential remained. In 2016, the assets and team spun back out, and the company relaunched as Regenerative Immunotherapies, later rebranding as SAB Biotherapeutics. The relaunched entity retained the rights to the transgenic-cattle technology and the commitment to developing its own pipeline of therapeutics.

The technology and its economics

The transgenic-cattle platform works through a deceptively simple principle: cattle carry ten pairs of chromosomes, and through advanced genetic engineering, SAB introduces human antibody genes while removing the corresponding bovine ones. The resulting animals have bovine physiology but human immune antibody production. When exposed to an antigen, they generate human antibodies that can be harvested from their blood serum — yielding far larger quantities than would be available from traditional fermentation or cell-culture methods.

From an economic perspective, the advantage is production speed and scale. Growing antibodies in bioreactors requires careful optimization of cell-culture conditions, media formulations, and contamination controls. The processes are expensive and time-consuming to scale. Cattle, by contrast, are self-scaling antibody factories — one animal can produce grams of antibodies per week, far more than a cell-culture system, and the supply is renewable. For companies developing multiple antibodies against the same antigen, or seeking rapid pivots to new targets, the throughput advantage is meaningful.

However, the technology carries operational costs that pure cell-culture approaches do not. Maintaining a herd of transgenic animals requires veterinary infrastructure, animal care, and animal-ethics oversight. The regulatory path for a product derived from transgenic-animal sources requires demonstrating safety and purity standards, including freedom from any potential zoonotic contamination. And the scale that is an advantage for bulk antibody production becomes less useful once a therapeutic enters clinical trials, where much smaller quantities are needed.

SAB’s business model pivots between these two economics: it uses the transgenic platform to produce antibodies for clinical development and, potentially, for therapeutic use, but also licenses the technology to larger pharmaceutical companies that lack in-house transgenic capacity. The licensing revenue provides cash flow while SAB’s own pipeline progresses.

From platform to pipeline

For most of its existence, SAB’s true business was contracting with larger firms to produce antibodies on a fee-for-service or licensing basis. Generating its own therapeutic pipeline has been the company’s long-term ambition, but also its challenge. In the mid-to-late 2010s, SAB began to shift its focus toward internally developed programs, particularly in infectious diseases and immunological disorders where antibody therapies have shown genuine benefit.

The company’s pipeline includes candidates against respiratory viruses and other infectious pathogens, as well as programs targeting autoimmune conditions. Each asset requires years of preclinical work, followed by Phase 1, Phase 2, and Phase 3 clinical trials before the possibility of regulatory approval. Biotech companies in SAB’s size range — with limited cash and a single platform — often face brutal choices about which programs to advance and which to deprioritize. For SAB, the question has been whether the transgenic platform’s genuine technical advantages are enough to justify the extended R&D spending before any drug reaches the market and generates revenue.

The company’s progress has been uneven. Like most early-stage biotechs, SAB has experienced clinical trial setbacks, delays in enrollment, and the need to revise strategic direction as evidence emerged about which indications were most tractable. That is the normal course of biotech development, but it has meant a long runway of losses and cash burn with no approved products to show for it.

Competitive position and market dynamics

The monoclonal-antibody market is mature and profitable. The earliest antibodies approved by the FDA — drugs like Remicade (infliximab) and Herceptin (trastuzumab) — became blockbusters, and the success of those programs motivated the entire industry. Today, dozens of antibody-based therapeutics are approved, and hundreds are in development across the industry’s major players. The science of antibody engineering is well understood; most companies use platform technologies not so different in principle from SAB’s approach, though the mechanics differ.

SAB’s competitive advantage is not that monoclonal antibodies are novel, but that its transgenic-cattle platform offers a way to generate them that is faster and yields larger quantities than some alternatives. That is a real edge in a specific context — particularly for companies seeking rapid antibody identification against novel targets — but it is not an insuperable barrier. SAB must compete primarily on the quality of its internal pipeline and on the skill with which it executes development, not solely on the elegance of its platform.

The company faces competition from major pharmaceutical and biotech firms, many with far deeper pockets and more diverse pipelines. If SAB’s own therapeutic programs prove effective, the company might attract acquisition interest from a larger player seeking to in-license the results. If not, the company risks becoming a platform vendor without a meaningful therapeutic franchise.

The path forward and the research case

SAB Biotherapeutics’ story is ultimately a bet on whether the transgenic-antibody platform can serve as the foundation for approved, marketed drugs. For investors or analysts studying the company, the critical metrics are the clinical progress of its pipeline programs and the quality of the data emerging from trials. Any potential acquisition offer would also be relevant, as it would signal that larger firms view SAB’s technology or assets as valuable enough to justify purchase.

The company’s annual reports (SEC CIK 0001833214) disclose the pipeline, the status of each program, and the cash runway — how many years of expenses the company can sustain on its existing balance sheet. Quarterly earnings calls highlight clinical updates and partnership developments. Given SAB’s biotech profile, the equity is speculative and appropriate only for investors with risk tolerance for years of losses and the possibility of partial or complete failure. The company’s future value rests almost entirely on whether one or more of its pipeline programs reaches market approval and generates substantial revenue, a binary outcome that makes SAB a classic venture-style equity stake rather than an income-producing or near-term dividend-growth opportunity.